"Pyrroles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Azoles of one NITROGEN and two double bonds that have aromatic chemical properties.
| Descriptor ID |
D011758
|
| MeSH Number(s) |
D03.383.129.578
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrroles".
Below are MeSH descriptors whose meaning is more specific than "Pyrroles".
This graph shows the total number of publications written about "Pyrroles" by people in this website by year, and whether "Pyrroles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 1 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 6 | 0 | 6 |
| 2004 | 3 | 1 | 4 |
| 2005 | 6 | 6 | 12 |
| 2006 | 3 | 2 | 5 |
| 2007 | 6 | 2 | 8 |
| 2008 | 10 | 3 | 13 |
| 2009 | 7 | 3 | 10 |
| 2010 | 3 | 4 | 7 |
| 2011 | 5 | 5 | 10 |
| 2012 | 6 | 4 | 10 |
| 2013 | 4 | 3 | 7 |
| 2014 | 5 | 4 | 9 |
| 2015 | 2 | 3 | 5 |
| 2016 | 6 | 2 | 8 |
| 2017 | 2 | 0 | 2 |
| 2018 | 4 | 0 | 4 |
| 2019 | 3 | 3 | 6 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 3 | 3 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrroles" by people in Profiles.
-
A simplified protocol for the automated production of 2-[18 F]fluoro-3-[2-((S)-3-pyrrolinyl)methoxy]pyridine ([18 F]nifene) on an IBA Synthera® module. J Labelled Comp Radiopharm. 2024 Jan; 67(1):31-36.
-
Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis. 2023 09 01; 29(9):1370-1379.
-
Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. J Immunother Cancer. 2022 03; 10(3).
-
Worldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(3):302-310.
-
5-ASAs Combined With a Biologic or Tofacitinib: Predetermined Cost-Effectiveness? Am J Gastroenterol. 2021 09 01; 116(9):1958-1959.
-
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma. Clin Cancer Res. 2021 06 15; 27(12):3317-3328.
-
Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
-
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 08; 19(8):1592-1601.e3.
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
-
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020 05; 21(5):671-684.